

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of respondent	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hr)	Total burden (in hr)
Individuals in racial and ethnic groups.	Survey Screener Questionnaire .....	1,500	1	2/60	50
LGBTQ+ individuals .....	Survey Screener Questionnaire .....	1,125	1	2/60	38
General population .....	Community Web-Panel Survey .....	4,050	1	30/60	2,025
Individuals in racial and ethnic groups.	Community Web-Panel Survey .....	600	1	30/60	300
LGBTQ+ individuals .....	Community Web-Panel Survey .....	450	1	30/60	225
General population .....	Focus Group Screener Questionnaire.	34	1	3/60	2
Individuals in racial and ethnic groups.	Focus Group Screener Questionnaire.	33	1	3/60	2
LGBTQ+ individuals .....	Focus Group Screener Questionnaire.	33	1	3/60	2
General population .....	Community Focus Group .....	25	1	1	25
Individuals in racial and ethnic groups.	Community Focus Group .....	25	1	1	25
LGBTQ+ individuals .....	Community Focus Group .....	25	1	1	25
<b>Total</b> .....	.....	.....	.....	.....	3,047

**Jeffrey M. Zirger,**  
*Lead, Information Collection Review Office,  
 Office of Public Health Ethics and  
 Regulations, Office of Science, Centers for  
 Disease Control and Prevention.*  
 [FR Doc. 2023–12358 Filed 6–8–23; 8:45 am]  
**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration for Children and Families**

**Proposed Information Collection Activity; Medical Health Assessment Form and Public Health Investigation Forms, Tuberculosis and Non-Tuberculosis Illness (Office of Management and Budget 0970–0509); Correction**

**AGENCY:** Office of Refugee Resettlement, Administration for Children and Families, United States Department of Health and Human Services.  
**ACTION:** Request for public comments; correction.

**SUMMARY:** The Administration for Children and Families (ACF) published a document in the **Federal Register** of June 1, 2023, concerning request for comments on a 3-year extension of the *Mental Health Assessment Form* (formerly the Health Assessment Form) and Public Health Investigation Forms, Active Tuberculosis (TB) and Non-TB Illness (Office of Management and Budget (OMB) #0970–0509, expiration December 31, 2023). The published notice contained an incorrect title and a typo in the *Description* section.

**SUPPLEMENTARY INFORMATION:**

**Correction**

In the **Federal Register** of June 1, 2023, in FR Doc. 2023–11627, the following corrections apply:

1. On page 35879, in the third column, the correct title is: Proposed Information Collection Activity; Mental Health Assessment Form and Public Health Investigation Forms, Tuberculosis and Non-Tuberculosis Illness (Office of Management and Budget 0970–0509).

2. On page 35880 in the third column, there is a typo in the second sentence. The sentence should read: In addition, ORR has written an instructional letter for the Mental Health Assessment Form to explain the purpose of the form and provide general guidance on completion to healthcare providers.

**DATES:** Comments due on the information collection proposed in 88 FR 35879 on or before July 31, 2023.

**ADDRESSES:** You can obtain copies of the proposed collection of information and submit comments by emailing [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov). Identify all requests by the title of the information collection.

**Mary B. Jones,**  
*ACF/OPRE Certifying Officer.*  
 [FR Doc. 2023–12334 Filed 6–8–23; 8:45 am]  
**BILLING CODE 4184–45–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. FDA–2020–D–1848]

**Clinical Drug Interaction Studies With Combined Oral Contraceptives; Guidance for Industry; Availability**

**AGENCY:** Food and Drug Administration, HHS.  
**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Clinical Drug Interaction Studies With Combined Oral Contraceptives.” This guidance is intended to help sponsors of investigational new drug applications and new drug applications evaluate the need for drug-drug interaction (DDI) studies with combined oral contraceptives (COCs), design such studies, and determine how to communicate DDI study results and risk mitigation strategies to address potential risks associated with increased or decreased exposure of COCs in labeling. The guidance finalizes the draft guidance “Clinical Drug Interaction Studies With Combined Oral Contraceptives” issued on November 23, 2020.

**DATES:** The announcement of the guidance is published in the **Federal Register** on June 9, 2023.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidances at any time as follows: